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Background: External cephalic version (ECV) is offered to reduce the number of Caesarean delivery indicated by
breech presentation which occurs in 3-4% of term pregnancies. ECV is commonly performed aided by the
application of aqueous gel or talcum powder to the maternal abdomen. We sought to compare gel with powder
during ECV on achieving successful version and increasing tolerability.
Method: We enrolled 95 women (≥ 36 weeks gestation) on their attendance for planned ECV. All participants
received terbutaline tocolysis. Regional anaesthesia was not used. ECV was performed in the standard fashion after
the application of the allocated aid. If the first round (maximum of 2 attempts) of ECV failed, crossover to the
opposing aid was permitted.
Results: 48 women were randomised to powder and 47 to gel. Self-reported procedure related median
[interquartile range] pain scores (using a 10-point visual numerical rating scale VNRS; low score more pain) were
6 [5-9] vs. 8 [7-9] P = 0.03 in favor of gel. ECV was successful in 21/48 (43.8%) vs. 26/47 (55.3%) RR 0.6 95% CI 0.3-1.4
P = 0.3 for powder and gel arms respectively. Crossover to the opposing aid and a second round of ECV was
performed in 13/27 (48.1%) following initial failure with powder and 4/21 (19%) after failure with gel (RR 3.9 95% CI
1.0-15 P = 0.07). ECV success rate was 5/13 (38.5%) vs. 1/4 (25%) P = 0.99 after crossover use of gel or powder
respectively. Operators reported higher satisfaction score with the use of gel (high score, greater satisfaction) VNRS
scores 6 [4.25-8] vs 8 [7-9] P = 0.01.
Conclusion: Women find gel use to be associated with less pain. The ECV success rate is not significantly different.
Trial registration: The trial is registered with ISRCTN (identifier ISRCTN87231556).
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The singleton fetus presents by the breech in 3-4% of
pregnancies at term [1]. The Term Breech Trial reported
in 2000 that perinatal mortality, neonatal mortality, or
serious neonatal morbidity was significantly lower for
the planned Caesarean section group than for the planned
vaginal birth group without any differences in maternal
mortality or serious maternal morbidity [2]. The trial re-
port has led to a rapid change in guideline [3], opinion [4]
and actual practice across the globe [5,6]. More recently,
guidelines have suggested a trial of breech vaginal birth
under a strict protocol in well informed women is
acceptable [7,8].* Correspondence: pctan@um.edu.my
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article, unless otherwise stated.Following the Term Breech Trial report, a survey of
Canadian providers reported 89% offer external cephalic
version (ECV) as a means of avoiding Caesarean delivery
for breech presentation [9]. Attempting ECV at term re-
duces the chance of non-cephalic births and of Caesarean
delivery [10]. In a recent literature review comprising 84
studies reporting on 12955 version, the pooled complica-
tion rate of ECV was 6.1% (mostly transient fetal heart
rate abnormalities), 0.24% for serious complications and
0.35% for emergency cesarean deliveries with the conclu-
sion that ECV is a safe procedure [11]. An ECV trial can
be cost-effective when compared to a scheduled Caesarean
for breech presentation provided the probability of suc-
cessful ECV is > 32% [12]. Tocolysis and regional anaes-
thesia improve the success rate of ECV [13].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tiparity (odds ratio [OR] 2.5; 95% confidence interval [CI]
2.3-2.8) and lower maternal weight (< 65 kg; OR 1.8; 95%
CI, 1.2-2.6) are clinical predictors for successful ECV [14].
Posterior placenta location (OR 1.9; 95% CI 1.5-2.4),
higher amniotic fluid index >10 (OR, 1.8; 95% CI 1.5-2.1)
and flexed breech position (OR 2.3; 95% CI 1.9-2.8) are
ultrasound predictors of successful ECV [15].
Talcum powder or gel is in common use in Malaysia
[16] and Australia [17] to aid ECV. Talcum powder was
originally used when ECV was reintroduced as a routine
clinical service in our centre. Recently some of our
providers have started using aqueous gel. The relative
tolerability and merit of powder or gel in aiding ECV is
not known. We performed a non-inferiority randomised
trial to compare powder against aqueous gel, powered on
self-reported procedure related maternal pain.
Methods
The trial was conducted in a university hospital deliver-
ing 6-7000 women a year in Kuala Lumpur, Malaysia.
Ethics oversight was provided by the University Malaya
Medical Center Medical Ethics Committee (approval refer-
ence no. 818.5 dated 20 October 2010). An internal grant
was provided by the University of Malaya (grant reference
RG370/11HTM) for the running of the trial. The trial
is registered with ISRCTN (identifier ISRCTN87231556)
and complied with the Declaration of Helsinki.
Providers approached potential participants as they
attended for their ECV appointment. A Patient Informa-
tion Sheet was provided and further query was fielded
by the enrolling provider. Written consent was obtained
from all who agreed to participate. In our centre, ECV
is performed by providers on duty in the delivery suite
who could be registrars or specialists. All had per-
formed ECVs previously but registrars were generally
less experienced.
Inclusion criteria were scheduled ECV, breech presen-
tation or transverse lie, singleton gestation, gestational
age ≥ 36 weeks, intact membranes, non-anomalous fetus
and reassuring fetal status on cardiotocogram. Women
were excluded if regular contractions were present, esti-
mated fetal weight < 2 kg, oligohydramnios (amniotic
fluid index < 5 cm), severe hypertension, recent antepar-
tum haemorrhage, uterine scar, related allergy and any
potential contraindication to vaginal delivery.
In our centre, ECV was performed within the Delivery
Suite. Women scheduled for ECV were instructed to be
fasted for six hours prior to their appointment. ECV was
typically scheduled for 36 to 38 weeks gestation. Prior
to their ECV attempt, all participants had a bedside ultra-
sound assessment and a cardiotocogram. 250 mcg terbuta-
line was administered subcutaneously 5-10 minutes prior
to attempting ECV. Regional anaesthesia was not offered.A participant was randomly allocated to “Powder” or
“Gel” by the sequential opening of the lowest numbered
sealed opaque envelope remaining just before the start
of ECV. Randomisation was on a one–to-one ratio. The
randomisation envelopes were prepared by an author
(NV who was not involved in recruitment) in a single
block of 100 using a computer generated randomisation
sequence obtained from http://www.random.org. The
numbered envelopes were prepared en-bloc at the begin-
ning of the study and arranged in sequence in a small
box in the Delivery Suite for providers to extract and
open to reveal the allocated intervention. Blinding of
providers and patients to the intervention was not
attempted as it was considered unachievable. We used
commercially available baby talcum powder and ultra-
sound aqueous gel.
After appropriate positioning of the participant for
ECV, powder or gel was applied to the woman’s abdo-
men by the operator. ECV was then carried out in a
standard fashion as previously described [18]. In the
first round, a maximum of 2 attempts at ECV were per-
mitted. An attempt comprised of a continuous maneu-
ver typically lasting not more than 2-3 minutes. Fetal
presentation and heart rate were then checked by ultra-
sound. If ECV was unsuccessful but the fetal heart rate
was normal and the woman was agreeable, a second at-
tempt was made with the same allocated aid. After com-
pletion of the first round of a maximum of two attempts,
the participant was asked to record her ECV related pain
score and the operator asked to provide a satisfaction
score with the use of the allocated aid, using a 10 point
visual numerical rating scale (VNRS - scored from 1 to 10,
marked as higher score more desirable result).
Following an unsuccessful first round of ECV if the
fetal status was reassuring on cardiotocogram (i.e. until
at least two fetal heart rate accelerations were observed
in the context of a normal baseline, baseline variability
and the absence of decelerations) and the provider and
woman were both willing, a second round of up to two
ECV attempts was permitted; with crossover to the op-
posing aid i.e. powder to gel, gel to powder. A further
terbutaline dose was given for the second round which
was conducted in similar fashion to the first round.
Finally, whether ECV was eventually successful or
otherwise, a post ECV cardiotocogram was done for all
participants to obtain a reassuring trace or until inter-
vention for an abnormal trace. If ECV was successful,
unless there was a specific indication for immediate
labour induction, the participants were allowed home
to await spontaneous labour. If ECV was unsuccessful,
women were also allowed home unless there was a spe-
cific indication for delivery, in which case Caesarean
delivery was offered on the same or the next day. We
did not prohibit a repeat ECV attempt on a future
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of recommending a planned Caesarean delivery (at ≥ 39
weeks gestation) for a viable singleton breech fetus.
Pregnancy outcome data were extracted from the
relevant clinical charts and other hospital records after
participants had been discharged following delivery
and transcribed onto a standardised case report form.
We predefined self-reported ECV related VNRS pain
score as primary outcome. The pain VNRS used was a
horizontal line with 10-points marked at regular inter-
vals from 1 to 10. Written instruction on the scale indi-
cated that low score is for worse and high score is for
better outcome. Participants were instructed to circle a
number on the line to indicate their procedure related
pain score.
ECV was considered a success if cephalic presentation
was demonstrated on ultrasound immediately after an
attempt. Secondary outcomes collected include opera-
tor’s VNRS satisfaction score (identical scale to the
pain VNRS described above) with the agent used, sig-
nificant post ECV cardiotocogram anomaly, cephalic
presentation at birth, Caesarean delivery (and indica-
tion), neonatal outcomes of Apgar score, umbilical
cord arterial blood pH and base deficit and neonatal
admission, gestational age at delivery, blood loss at
delivery and birth weight.
A previous study comparing powder and gel during
ECV was not available to provide pilot data for sample size
calculation. We took a 1-point increase on the 10-point
VNRS for pain as non-inferior for the gel compared to
powder. We assume the standard deviation of VNRS pain
score to be 1.5. Taking alpha 0.05 and beta 0.1, applying
the Student t test, at least 78 participants were required
for a suitably powered study (calculated on http://www.
sealedenvelope.com/power/continuous-noninferior/). We
subsequently increased sample size by 15% after factoring
in the possibility that VNRS pain score may not be nor-
mally distributed and the Mann Whitney U test will
need to be applied in place of the t test resulting in a
calculated sample size of 90 participants. We prepared
100 randomisation envelopes for enrollment in the event
of drop outs, unforeseen post randomisation exclusions
and other errors.
For assessment of major harms of the study, we looked
at procedure related Caesarean delivery, fetal or neonatal
death, neonatal hypoxic-ischaemic encephalopathy and
major abruptio placenta.
Data was entered into SPSS 17 (SPSS Inc., Chicago, IL).
Primary analysis was planned to be per protocol if there
were protocol violations as is appropriate for a non-
inferiority hypothesis to minimise the mistaken rejection
of the null hypothesis of a significant difference between
the interventions compared to intention to treat analysis
[19]. The normality of distribution of continuous variables(i.e. maternal age, weight, height and body mass index,
gestational age at recruitment, estimated fetal weight, am-
niotic fluid index, maternal pain VNRS score, provider
satisfaction VNRS score, gestation at delivery, estimated
blood loss at delivery, birth weight, Apgar scores and um-
bilical arterial blood pH and base deficit) was checked
with the 1-sample Kolmogorov-Smirnov test. Normally
distributed data was expressed in mean ± standard devi-
ation and non-normally distributed or ordinal data as me-
dian [interquartile range]. The Student t test was applied
in the analyses of normally distributed continuous vari-
ables (i.e, maternal age, weight, height, body mass index,
estimated fetal weight, amniotic fluid index, gestation at
delivery, birth weight and umbilical arterial blood pH
and base deficit) with the Mann Whitney U test used in
preference if data distribution was non-normal or or-
dinal in nature (i.e. gestational age at recruitment, parity,
maternal pain VNRS score, provider satisfaction VNRS
score, estimated blood loss at delivery and Apgar scores).
To further support the robustness of our findings of sig-
nificant differences, although the data were both ordinal
and non-normally distributed for the maternal pain VNRS
score and provider satisfaction VNRS score, we also ana-
lysed these parameters with the Student t test and add-
itionally expressed the data in mean ± standard deviation.
Two by two categorical datasets were analyzed by Fisher’s
exact test (nulliparity, ECV successes at various attempts,
cross-over rates, CTG abnormality after ECV, cephalic
presentation at birth and neonatal admission) and larger
categorical datasets by the Chi square test (ethnicity, type
of breech presentation, placenta location, mode of delivery
and indication for Caesarean delivery). We performed a
multivariable logistic regression analysis as it was noted
that several important characteristics (i.e. maternal age,
multiparity, maternal weight, placenta location, type of
breech and amniotic fluid index) of the participants,
characteristics that could influence ECV success in the
trial arms were somewhat different (though not at the
5% significance level), to control for these characteristics
in a hypothesis generating exercise on the adjusted impact
of powder versus gel on ECV success. All tests were 2
sided and P < 0.05 was taken as a level of significance.
Result
The trial recruited from January 18 2011 and the last
participant was delivered by December 23 2012. Figure 1
depicts the flow of trial participants including crossover
to the opposing aid after initial ECV failure. Ninety five
women, all with fetuses in breech presentation were
enrolled and then randomized: 48 to powder and 47 to
gel. Recruitment ceased when all 100 numbered enve-
lopes were used. Five numbered envelopes could not
be accounted for (two allocated to powder and three
allocated to gel). ECV was performed by 37 different
Randomised to Powder
n = 48
Crossover to Gel
n = 13 (48.1%)
Failedl ECV
n = 27 (56.2%)
Eligible women attending for ECV
enrolled into trial
N = 95
Successful ECV
n = 21 (43.8%)
Failed ECV
n = 8 (61.5%)
Successful ECV
n = 5 (38.5%)
Final ECV Outcome
(Failure)
n = 14 (no crossover)
n = 8 (crossover)
Total n = 22 (45.8%)
Final ECV Outcome
(Success)
n = 21 (initial)
n = 5 (crossover)
Total n = 26 (54.2%)
Randomised to Gel
n = 47
Sucessful ECV
n = 26 (55.3%)
Failed ECV
n = 21 (44.7%)
Crossover to Powder
n = 4 (19.0%)
Successful ECV
n = 1 (25.0%)
Failed ECV
n = 3 (75.0%)
Final ECV Outcome
(Success)
n = 26 (initial)
n = 1 (crossover)
Total n = 27 (57.4%)
Final ECV Outcome
(Failure)
n = 17 (no crossover)
n = 3 (crossover)
Total n = 20 (42.6%)
Figure 1 Recruitment flow chart for a randomised trial of talcum powder versus aqueous gel for external cephalic version.
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from 1 to 9. Of the provider (a registrar) who performed
ECV for nine participants, five of the participants were
randomised to gel and four to powder. Specialists per-
formed ECV in 12 of the participants (six participants
each was allocated to powder and gel). All participants
received powder or gel as allocated for their first round
of ECV, so intention to treat analysis and per protocol
analysis yielded identical results. Following successful
ECV, 6/53 (11.3%) reverted spontaneously to non-cephalic
presentation. There was no spontaneous version to ceph-
alic after failed ECV. With the exception of one woman
who had a vaginal breech delivery, the other 47 partici-
pants with non-cephalic presentation at birth were all
delivered by Caesarean. Of the 47 women with cephalic
presentation who underwent trial of labour, 39 (83.0%)
delivered vaginally. Although not prohibited, no repeat
ECV was performed.
Table 1 depicts the characteristics of the participants
stratified according to randomization to powder or gel.
Participants’ characteristics across the trial arms were
similar (P > 0.05).
Table 2 depicts the primary outcome and ECV suc-
cess outcome at each attempt stratified according to
randomization to powder or gel. The primary outcome
of ECV related maternal pain as expressed using a 10-
point visual numerical rating scale (VNRS) was signifi-
cantly worse with talcum powder compared to aqueousgel median score [interquartile range] 6 [5-9] vs. 8 [7-9]
P = 0.03. First round ECV success rate between powder
and gel arms was not different 21/48 (43.8%) vs. 26/47
(55.3%) RR 0.6 95% CI 0.3-1.4 P = 0.31. Including cross-
overs, ECV success rates were 54.2% versus 57.4% for the
powder against gel arms respectively as originally allo-
cated. Post hoc, we considered the rate of crossovers after
a failed initial round of ECV attempts. 13/27 (48.1%) who
failed ECV with powder had a further round of ECV at-
tempts with gel compared to only 4/21 (19.0%) who failed
ECV with gel crossing to the use of powder for a further
round of ECV, P = 0.07. We also evaluated ECV success
rate taking into account all 164 ECV attempts – there
were 77 attempts with powder and 87 with gel: respective
success rates were 22/77 (28.6%) vs. 31/87 (35.6%) RR 0.8
95% CI 0.6-1.2 P = 0.40, again not significantly different.
Table 3 shows the other secondary outcomes stratified
according to randomisation to powder or gel. Providers/
operators expressed less satisfaction with the use of pow-
der compared to gel median [interquartile range] VNRS
score 6 [4.25-8] vs. 8 [7-9] P = 0.01. Other secondary out-
comes of abnormal cardiotocogram after ECV needing
Caesarean delivery, gestational age at delivery, cephalic
presentation at birth, Cesarean delivery (and indication),
blood loss at delivery and a range of neonatal outcomes
were not different.
On appraising Table 1, although all characteristics on
bivariate analysis had P < 0.05, there was disparity in
Table 1 Characteristics of trial participants according to
randomization to talcum powder or aqueous gel
Powder n = 48 Gel n = 47 P value
Mean ± standard deviation,
Median [interquartile range]
or Number (%)
Age (years) 31.1 ± 4.5 29.5 ± 4.0 P = 0.07
Gestational age (weeks) 37.5 [37.4–7.9] 37.8 [37.4–38.2] P = 0.22
Parity 1 [0–2] 0 [0–2] P = 0.08
Nulliparous 19 (39.6) 27 (57.8) P = 0.10
Weight (kg) 67.6 ± 9.4 71.1 ± 10.9 P = 0.10
Height (m) 1.55 ± 0.06 1.57 ± 0.06 P = 0.11
Body Mass Index 28.1 ± 4.5 28.7 ± 4.0 P = 0.50
Ethnicity P = 0.94
Malay 35 (51.5) 33 (48.5)
Chinese 6 (12.5) 5 (10.6)
Indian 4 (8.3) 5 (10.6)
Others 3 (6.3) 4 (8.5)
Estimated fetal weight (kg)* 2.9 ± 0.3 2.9 ± 0.3 P = 0.70
Amniotic Fluid Index* 12.2 ± 3.6 11.6 ± 3.2 P = 0.43
Type of breech* P = 0.15
Flexed 21 (43.8) 28 (59.6)
Extended 27 (56,3) 19 (40.4)
Placenta location* P = 0.38
Anterior 24 (50.0) 17 (36.2)
Posterior 21 (43.8) 27 (57.4)
Fundal 3 (6.3) 3 (6.4)
*Determined by ultrasound prior to ECV.
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breech and placenta location with P values close to 0.05.
Post hoc, we controlled for maternal age, multiparity,
maternal weight, placenta location, type of breech and
amniotic fluid index in a multivariable logistic regression
analysis. After adjustment, the adjusted odds ratio (AOR)
was 2.1 95% CI 0.8-5.8 P = 0.14 for gel compared to pow-
der on ECV success, a non-significant result.
There was no major unintended harm arising from the
trial to our knowledge.Discussion
Our trial finds that ECV with gel was less painful for
women, more satisfying for the operator to use but the
rate of ECV success was not significantly different: our
sample size was not sufficient to address the latter out-
come. We find gel to be both non-inferior and superior
to powder in terms of self-reported procedure related
maternal pain. This is possibly due to the superior anti-
abrasive effect of gel yet coupled with sufficient grip for
the operator to successfully perform the ECV.An anti-abrasive agent typically ultrasonic gel, talcum
powder or mineral oil is routinely applied to the abdo-
men during ECV [16,17] purportedly to reduce pain, to
prevent abdominal wall injury and to smooth the move-
ment of the operator’s hands as the fetal poles are rotated
to their desired position. We performed a PubMed search
(via http://www.ncbi.nlm.nih.gov/pubmed) on August 12
2013 using the terms “external cephalic version powder”
or “external cephalic version gel” without any limitation:
no study relevant to the performance of gel and powder
as an aid to ECV was identified. There seemed to be a
complete lack of information on the performance of
these aids.
Our data suggested that gel compared to powder
may improve ECV success with AOR 2.1 95% CI 0.8-
5.8 P = 0.14. However this finding is not significant and
the confidence interval is wide. Meta-analyzes show
that beta-mimetics may increase cephalic presentation
in labour after ECV rate by OR 1.38 (95% CI 1.03-1.85)
[13] and regional anaesthesia may improve ECV success
rate by OR 1.58 (95% CI 1.29-1.93) [20]. Given the simpli-
city of gel application at ECV as an intervention and the
potential magnitude of benefit as suggested by our data,
further powered study is warranted. A total of 626 women
(applying Fisher’s exact test) will need to be enrolled for a
trial to have 80% power to detect the observed crude dif-
ference (43.8% vs. 55.3%) in ECV success rates between
powder and gel. Using the first round ECV success rates
of 43.8% vs. 55.3% with powder and gel respectively, a
posteriori our trial had only 14.5% power to detect such
a difference with alpha set at 0.05.
We noticed a trend in favour of powder to gel compared
to gel to powder cross- overs after ECV failure with the
originally allocated aid; 13/27 (48.1%) versus 4/21 (19.0%)
P = 0.07. We did not collect information on the decision
making process involved in the crossover but it seemed
likely that operators had a major influence in the process
as the trend appeared to favour powder to gel crossover
more than gel to powder crossover in tandem with the
higher satisfaction for gel use expressed by operators. This
trend is counterintuitive to the finding that powder was
associated with more maternal pain which one would
expect to reduce powder to gel crossover if viewed from
the maternal perspective.
Our trial has strengths and limitations. We analyzed per
protocol as is appropriate with our non-inferiority trial de-
sign. Incomplete datasets were minimal. Our trial was
properly powered a priori and power calculation indicated
our trial has 80% power to detect the observed difference
in procedure related maternal pain (calculator available
through https://www.dssresearch.com/KnowledgeCenter/
toolkitcalculators/statisticalpowercalculators.aspx). As for
limitations, ideally a “placebo” (no aid) arm should be in-
cluded to establish the superiority of either powder or gel
Table 2 Primary outcome and external cephalic version (ECV) success after each attempt according to randomisation
to talcum powder or aqueous gel
Powder n = 48 Gel n = 47 P value Relative risk (95% confidence interval)
Mean ± standard deviation, Median
[interquartile range] or Number (%)
Primary outcome
ECV Related Maternal Pain VNRS* 6 [5–9] 8 [7–9] P = 0.03
6.9 ± 2.2 7.9 ± 1.7 P = 0.02
ECV outcomes
First round of ECV (up to 2 attempts) † P = 0.31 RR 0.6 (95% CI 0.3–1.4)
Successful 21 (43.8) 26 (55.3)
Failed 27 (56.2) 21 (44.7)
First round of ECV (up to 2 attempts)
First ECV attempt P = 0.99 RR 1.0 (95% CI 0.7–1.5)
Successful 20/48 (41.7) 19/47 (40.4)
Failed 28/48 (58.3) 28/47 (59.6)
Second ECV attempt (failed 1st attempt) n = 56 P = 0.07
Successful 1/28 (3.6) 7/28 (25.0)
Failed 23/28 (82.1) 17/28 (60.7)
Not attempted 4/28 (14.3) 4/28 (14.3)
Second round of ECV (up to 2 attempts)
Crossed-over (after failed 1st round) n = 48 To gel To powder P = 0.07 RR 3.9 (95% CI 1.0–15)
Yes 13/27 (48.1) 4/21 (19.0)
No 14/27 (51.9) 17/21 (81.0)
3rd ECV attempt (after cross-over) n = 17 Using gel Using powder P = 0.99 RR 0.8 (95% CI 0.1–6.0)
Successful 4/13 (30.8) 1/4 (25.0)
Failed 9/13 (69.2) 3/4 (75.0)
4th ECV attempt (after failed 3rd attempt) n = 12 Using gel Using powder P = 0.80
Successful 1/9 (11.1) 0/3 (0.0)
Failed 2/9 (22.2) 1/3 (33.3)
Not attempted 6/9 (66.7) 2 /3(66.7)
Cross-over round P = 0.99 RR 1.9 (95% CI 0.2–23)
Successful 5/13 (38.5) 1/4 (25.0)
Failed 8/13 (61.5) 3/4 (75.0)
Powder Gel
Final ECV outcome (cross-over included)‡ P = 0.84 RR 0.9 (95% CI 0.4–2.0)
Successful 26 (54.2) 27 (57.4)
Failed 22 (45.8) 20 (42.6)
*Pain 10 point visual numerical rating scale (VNRS) with range from 1 to 10 (lower score, more pain) self-scored by participants immediately after up to 2 attempts
completed (successful or otherwise) with allocated powder or gel.
†Defined as cephalic presentation confirmed by ultrasound following ECV with allocated powder or gel.
‡Defined as cephalic presentation confirmed by ultrasound following ECV with allocated powder or gel and also after a crossover (after initial failure) to gel or
powder if attempted analysed according to the original allocation to powder or gel.
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commonly used aids to ECV in our setting, which in our
view is ethically robust. Double blinding is impossible but
we felt it is unlikely that the primary outcome we evalu-
ated would be biased by the open design. However, it is
not possible to totally exclude biases arising frominteractions between providers, patients and the aid used.
We found no evidence that operators tried less hard to
achieve success (e.g. in foregoing second attempts or not
applying adequate pressure during ECV) with a particular
aid though they generally liked gel better. Cross-over to
gel after failure with powder was more frequent compared
Table 3 Secondary outcomes according to randomisation to talcum powder or aqueous gel to aid external cephalic
version (ECV)
Powder n = 48 Gel n = 47 P value Relative risk (95% confidence interval)
Mean ± standard deviation, Median
[interquartile range] or Number (%)
Secondary outcomes
Providers’ Satisfaction VNRS* 6 [4.25–8] 8 [7–9] P = 0.01
6.3 ± 2.5 7.6 ± 1.9 P < 0.01
Abnormal cardiotocogram after ECV 0 (0) 0 (0) †
Gestational age at delivery 39.2 ± 1.0 39.1 ± 1.1 P = 0.69
Cephalic presentation at birth 24 (50.0) 23 (48.9) P = 0.99 RR 1.0 (95% CI 0.7–1.5)
Mode of delivery P = 0.94 RR 0.9 (95% CI 0.3–2.0)
Caesarean delivery 27 (56.3) 28 (59.6) P = 0.84
Instrumental vaginal 3 (6.3) 3 (6.4)
Spontaneous vaginal 18 (37.5) 16 (34.0)
Indication for Caesarean delivery P = 0.99
Malpresentation 22 (84.6) 24 (85.7)
Non-reassuring fetal status 2 (7.7) 2 (7.1)
Failure to progress in labour 2 (7.7) 2 (7.1)
Estimated blood loss at delivery (ml) 300 [200–425] 400 [200–400] P = 0.40
Birth weight (kg) 3.1 ± 0.3 3.1 ± 0.3 P = 0.92
Apgar score (1 min) 9 [9] 9 [9] P = 0.67
Apgar score (5 min) 10 [10] 10 [10] P = 0.99
Umbilical artery blood pH 7.28 ± 0.07 7.29 ± 0.09 P = 0.53
Umbilical artery blood base deficit 3.8 ± 3.3 4.2 ± 5.3 P = 0.73
Neonatal admission‡ 4 (8.3) 2 (4.3) P = 0.68 RR 2.0 (95% CI 0.4–12)
*Satisfaction 10 point visual numerical rating scale (VNRS) with range from 1 to 10 (high score, greater satisfaction) self-scored by providers attempting ECV
immediately after attempt (successful or otherwise) was completed with powder or gel as originally allocated.
†Not calculable: two zero cells.
‡Of the four neonatal admissions for the powder arm (two was for transient tachypnoea of the newborn, one for a suspected cephalhaematoma following
vacuum delivery and another for further observation following 1 minute Apgar of 5 with umbilical arterial cord pH of 6.99 and a base deficit of 15. A. Of the two
neonatal admissions for the gel arm, one was for transient tachypnoea of the newborn and another for neonatal jaundice.
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have been more confident with gel. This potential bias
would tend to push downstream results such as presenta-
tion at birth and Caesarean delivery rate towards null on
an intention to treat basis if gel was superior. We per-
formed a number of post hoc analyzes on ECV success
per attempt with each aid and we also adjusted for char-
acteristics that might confound: we did not find any sig-
nificant difference on these (but likely underpowered)
analyses. Our trial was performed by 37 providers, mostly
by registrars. It is possible the ECV experience or expertise
of the provider could influence the ECV success rate but
specialists were not more likely to have performed ECV
with a particular aid and we find no evidence amongst
registrars who had performed a larger number of ECVs
that allocation to a particular aid was uneven. We believe
our findings to be generalisable to other populations
undergoing ECV without anaesthesia as our ECV protocol
followed established guideline [1].Conclusion
The use of aqueous gel as an aid to ECV is both non-
inferior and superior to talcum powder in terms of self-
reported procedure related maternal pain. ECV success
rate is not significantly different but our trial was not
powered to assess this outcome.Ethics approval
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